Nimbus Therapeutics has raised $105 million to put its allosteric TYK2 inhibitor through a clutch of phase 2 clinical trials. The multifront midphase program is designed to determine whether the drug ...
Sotyktu (deucravacitinib), the tyrosine kinase 2 (TYK2) inhibitor for psoriasis from Bristol Myers Squibb Co., is “a good first-in-class” drug, said Nimbus Therapeutics LLC CEO Jeb Keiper, but his ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through its powerful computational discovery engine, today announced initiation of a ...
Computational drug discovery firm Nimbus Therapeutics has reached a multiyear partnership with Charles River Laboratories to advance programs across the biotech’s therapeutic areas of expertise.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus ...
Celgene and the computational chemistry company Nimbus Therapeutics are teaming up to advance R&D on small molecules that could treat a suite of immunology conditions. One Nimbus program is designing ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, will host a webcast seminar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results